Inositec was founded in December 2015 as a spin-off of ETH Zurich. Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications.
Inositec成立于2015年12月，是苏黎世联邦理工学院的一个分支机构。Inositec AG正在基于其专有的磷酸肌醇（IP6）类似物Inositune™平台，开发用于软组织钙化疾病的一流疗法。 该公司的牵头计划致力于解决血管和肾脏钙化疾病，包括孤儿适应症。
